Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its partner Eisai Co Ltd (TYO:4523) announced on Thursday that Hong Kong has approved Leqembi (lecanemab) for Alzheimer's disease.
The treatment is for patients with mild cognitive impairment or mild dementia.
Hong Kong joins the United States, Japan, China and South Korea in approving the drug.
Developed by BioArctic and Eisai, Leqembi reduces amyloid-beta plaques in the brain and slows cognitive decline. Eisai has submitted applications for approval in 13 other countries and regions.
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Clarivate adds Pathway Maps to OFF-X, boosting drug safety intelligence
GSK to acquire efimosfermin in USD2bn deal to expand hepatology pipeline
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research
Hoth Therapeutics reports positive HT-KIT preclinical results
Solve M.E. announces Dr Akiko Iwasaki as first recipient of inaugural ME/CFS Catalyst Award
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
RemeGen reports positive phase 3 results for disitamab vedotin in advanced urothelial carcinoma
Lilly and Purdue University expand collaboration, announce investment
AstraZeneca's Imfinzi improves disease-free survival in early bladder cancer trial